The Georgian Medical Journal (GMJ), published by PHIG, has released The peptide boom: a critical appraisal of evidence, patient safety risks, and regulatory failure in the experimental wellness peptide market (published 26 August 2026; DOI 10.66636/gmj.v1.i3.a200; source: Crossref).
The article reviews the evidence behind peptides sold for wellness and performance, the risks for patients, and gaps in regulation — a topic close to PHIG’s work on consumer product safety.
All GMJ articles are open access and permanently citable through Crossref DOIs. Browse the journal at gmj.ge.
The appraisal examined the clinical and pre-clinical evidence base for a class of bioactive peptide products marketed to Georgian consumers as supplements with anti-ageing, immune-modulating, and regenerative properties. The reviewers found that the available human trial data were insufficient to support the therapeutic claims made in marketing materials, and that several products were being sold under supplement classification to circumvent pharmaceutical regulatory requirements.
The paper notes a pattern observed across multiple post-Soviet markets: experimental compounds with some pre-clinical data are repositioned as “dietary supplements” when regulatory approval for pharmaceutical use would require substantially more evidence. This classification gap creates consumer safety risks that national regulatory frameworks have not yet addressed.
The Georgian Medical Journal (gmj.ge) is PHIG’s open-access peer-reviewed publication, indexed in multiple international databases. The full article is available open access via the GMJ website. PHIG has submitted the paper’s conclusions to the Georgian Food Safety Agency as part of ongoing regulatory dialogue on supplement market oversight.
Professor, David Tvildiani Medical University | Chair, Public Health Institute of Georgia | Founder, Accréditation Sans Frontières
